In dialysis-dependent patients, those on denosumab for fracture risk had a 36% higher MACE rate than those on bisphosphonates ...

They are both given as a subcutaneous injection. The most common side effects for Evenity are joint pain and headaches, while ...

That reimbursement would be based on using an out of network provider, and would therefore reimburse you a lesser amount than it cost. Another injection covered under Part D is denosumab. Denosumab is ...

Decisions by both agencies are expected in the second half of 2025, according to a statement. Denosumab is marketed under the ...

Pharmac is widening access to a medicine called denosumab for people with osteoporosis. A higher dose of the medicine will ...

Access to denosumab for people with high blood calcium will be from 1 February 2025. Widened access to denosumab for people with osteoporosis will be from 1 March 2025. Pharmac can widen access to ...

New Zealand’s medicine-funding agency Pharmac is widening access to a medicine called denosumab for people with osteoporosis.

Taken alongside Prolia/Xgeva, the brands account for well over 40% of Amgen's current revenues. Other companies working on biosimilar versions of denosumab include Samsung Bioepis, Celltrion, and ...

Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the originator in ...